Pluristem Therapeutics, Inc.
Period Ending Jun 30, 2013 Jun 30, 2012 Jun 30, 2011 Jun 30, 2010
Total Revenue 679 716 - -
Cost of Revenue 20 21 - -
Gross Profit 659 695 - -
Operating Expenses
Research and Development 17,233 9,158 6,629 4,301
Sales, General and Admin. 5,649 6,568 4,485 3,138
Non-Recurring Items - - - -
Other - - - -
Operating Income (22,223) (15,031) (11,114) (7,439)
Income From Continuing Operations
Add'l Income/Expense Items 1,068 237 266 -
Earnings Before Interest and Tax (21,155) (14,794) (10,848) (7,453)
Interest Expense - - - -
Earnings Before Tax (21,155) (14,794) (10,848) (7,453)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (21,155) (14,794) (10,848) (7,453)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (21,155) (14,794) (10,848) (7,453)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (21,155) (14,794) (10,848) (7,453)